A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Nintedanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 06 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Jan 2018.
- 10 Dec 2015 Accrual till date is 0% according to United Kingdom Clinical Research Network.
- 17 Jul 2015 New source identified and integrated (European Clinical Trials Database record:EudraCT2012-004295-19)